8,365 reports of this reaction
5.3% of all RIBAVIRIN reports
#2 most reported adverse reaction
ANAEMIA is the #2 most commonly reported adverse reaction for RIBAVIRIN, manufactured by Bausch Health US, LLC. There are 8,365 FDA adverse event reports linking RIBAVIRIN to ANAEMIA. This represents approximately 5.3% of all 157,291 adverse event reports for this drug.
RIBAVIRIN has an overall safety score of 85 out of 100. Patients taking RIBAVIRIN who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among RIBAVIRIN users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for RIBAVIRIN:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 8,365 FDA reports for RIBAVIRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 5.3% of all adverse event reports for RIBAVIRIN, making it one of the most commonly reported side effect.
If you experience anaemia while taking RIBAVIRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.